科笛-B:CU-20401(重组突变胶原酶)治疗颏下脂肪堆积II期临床试验达到主要终点

格隆汇资讯
29 Nov 2024

格隆汇11月29日丨科笛-B(02487.HK)发布公告,集团的潜在1类新药CU-20401(重组突变胶原酶)于中国开展的用于治疗颏下脂肪堆积的II期临床试验已获得顶线数据。数据显示,该临床试验达到主要研究终点,结果具有统计学显着性及临床意义。该临床试验是一项多中心、随机、双盲及安慰剂对照试验,旨在评估CU-20401治疗中度至重度颏下脂肪堆积患者的有效性和安全性,共入组108例受试者。分析...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10